Sanofi is to buy Principia Biopharma for up to $3.68 billion, adding a potential multiple sclerosis drug to its pipeline. The French pharma said it will pay $100 per share in cash for San ...

The French drugmaker added rilzabrutinib to its pipeline with its $3.7B acquisition of Principia Biopharma in 2020. Sanofi (NASDAQ:SNY) announced Tuesday that rilzabrutinib, an oral therapy for an ...

The FDA review – which is due to be completed by 28th September – revolves around the results of the HERCULES trial which ...

That's because the same group previously was in charge of Principia Biopharma which wound up being acquired by Sanofi (SNY) ...